SLC5A2 and susceptibility to pneumonia measurement: Regarding pneumonia occurrence, there was no significant difference between the SGLT2 and non-SGLT2 inhibitor groups in either the crude (4.5% vs. 4.2%; HR, 1.06; CI 95%, 0.97–1.15; p = 0.20) or PS-matched analysis (4.5% vs. 4.4%; HR, 1.03; CI 95%, 0.91–1.16; p = 0.62) (Table 4, Supplementary Figure S4).